Articles with "pfizer inc" as a keyword



Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz242.024

Abstract: Abstract Background Palbociclib, the first clinically available oral CDK4/6 inhibitor, in combination with endocrine therapy has become standard of care for HR+/HER2- advanced/metastatic breast cancer (MBC). No real-world studies have examined relative effectiveness of palbociclib… read more here.

Keywords: real world; palbociclib; pfizer inc; palbociclib plus ... See more keywords

P-1194. Comparison of COVID-19 inpatient burden in hospitalized children age < 5 years, by SARS-CoV-2 variant

Sign Up to like & get
recommendations!
Published in 2025 at "Open Forum Infectious Diseases"

DOI: 10.1093/ofid/ofae631.1378

Abstract: Abstract Background COVID-19 disease severity has fluctuated with emergence of variants. To investigate disease severity in children, we analyzed clinical resource utilization among children hospitalized for COVID-19 during different variant periods in the United States.… read more here.

Keywords: delta omicron; delta; pre delta; pfizer inc ... See more keywords

P-2047. Public Health Impact and Economic Value of an Additional Dose of Pfizer-BioNTech XBB.1.5-adapted COVID-19 Vaccine for Older Adults in the United States

Sign Up to like & get
recommendations!
Published in 2025 at "Open Forum Infectious Diseases"

DOI: 10.1093/ofid/ofae631.2203

Abstract: Abstract Background To assess the public health impact and economic value of an additional dose of BNT162b2 XBB.1.5-adapted COVID-19 vaccine 6 months after initial dose for those aged ≥65 years, compared to a single dose… read more here.

Keywords: pfizer inc; public health; additional dose; pfizer ... See more keywords

P-2062. COVID-19 XBB.1.5-adapted Vaccine Uptake in Immunocompromised Individuals Using Tokenized State Vaccine Registries

Sign Up to like & get
recommendations!
Published in 2025 at "Open Forum Infectious Diseases"

DOI: 10.1093/ofid/ofae631.2218

Abstract: Abstract Background Immunocompromised individuals experience a disproportionate burden of COVID-19-associated hospitalization and death. COVID-19 vaccine uptake has declined over time. We evaluated XBB.1.5-adapted vaccine uptake, regardless of brand, during the 2023-2024 season among immunocompromised persons… read more here.

Keywords: pfizer inc; xbb adapted; vaccine uptake; pfizer ... See more keywords
Photo by _louisreed from unsplash

Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: Eight Years of US Surveillance (2009–2016)

Sign Up to like & get
recommendations!
Published in 2017 at "Open Forum Infectious Diseases"

DOI: 10.1093/ofid/ofx163.1196

Abstract: Abstract Background A pneumococcal polysaccharide vaccine (PPSV23) has been available for use in adults ≥65 years old since 1983 with vaccination rates of ~65% in the past decade. A conjugate vaccine (PCV13) has been recommended… read more here.

Keywords: research; adult; pfizer inc; serotype ... See more keywords

SAT0686 Major adverse cardiovascular events: risk factors in patients with ra treated with tofacitinib

Sign Up to like & get
recommendations!
Published in 2017 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2017-eular.2434

Abstract: Background Patients (pts) with RA have increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors. Tofacitinib is an oral JAK inhibitor for the treatment of… read more here.

Keywords: pfizer inc; risk; mace; mace risk ... See more keywords

THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies

Sign Up to like & get
recommendations!
Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.1459

Abstract: Background Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral JAK inhibitor for the treatment of PsA. Objectives To investigate changes in… read more here.

Keywords: incidence; pfizer; pfizer inc; treatment ... See more keywords

SAT0220 Evaluation of live zoster vaccine in a subset of patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, and adalimumab with methotrexate: results from a phase 3b/4 randomised trial

Sign Up to like & get
recommendations!
Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.1469

Abstract: Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA are at increased risk for herpes zoster (HZ) and this risk is further increased with tofacitinib… read more here.

Keywords: ada mtx; pfizer inc; pts received; pfizer ... See more keywords

SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes

Sign Up to like & get
recommendations!
Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.3048

Abstract: Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signalling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk of venous thromboembolic events (VTE) in patients (pts) with rheumatoid… read more here.

Keywords: shareholder; pfizer inc; inc employee; pfizer ... See more keywords

SAT0330 Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis

Sign Up to like & get
recommendations!
Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.3490

Abstract: Background Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function and homeostasis signal through JAKs, and reductions in mean lymphocyte count over time… read more here.

Keywords: pfizer; pfizer inc; bristol myers; eli lilly ... See more keywords

FRI0144 JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.1196

Abstract: Background Inflammatory arthritides affect joints variably despite systemic inflammatory cues. Anatomical site-specific differences have been seen in the transcriptome and function of synovial fibroblasts from different joints,1 including evidence that some joints in rheumatoid arthritis… read more here.

Keywords: pfizer; pfizer inc; treatment; oral strategy ... See more keywords